Georgia Code
Part 1 - Schedules, Offenses, and Penalties
§ 16-13-25. Schedule I

The controlled substances listed in this Code section are included in Schedule I:
(AA) Levomoramide;
(BB) Levophenacylmorphan;
(CC) Morpheridine;
(DD) Noracymethadol;
(EE) Norlevorphanol;
(FF) Normethadone;
(GG) Norpipanone;
(HH) Phenadoxone;
(II) Phenampromide;
(JJ) Phenomorphan;
(KK) Phenoperidine;
(LL) Piritramide;
(MM) Proheptazine;
(NN) Properidine;
(OO) Propiram;
(PP) Racemoramide;
(QQ) Trimeperidine;
(RR) 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide (AH-7921);
(SS) 3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide (U-47700);
(TT) Methyl-AP-237;
(UU) Tianeptine;
(AA) 1-methyl-4-phenyl-4-propionoxypiperidine;
(BB) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine;
(CC) Reserved;
(DD) N-ethyl-3, 4-methylenedioxyamphetamine;
(EE) Reserved;
(FF) 2,5-Dimethoxy-4-Ethylamphetamine;
(GG) Cathinone;
(HH) Reserved;
(II) PEPAP (1-(2-phenethyl)-4 phenyl-4-acetoxypiperide);
(JJ) Reserved;
(KK) Para-methoxymethamphetamine (PMMA);
(LL) 4,4’-dimethylaminorex;
(MM) Reserved;
(NN) Reserved;
(OO) 3,4-Methylenedioxy-N-Ethylamphetamine;
(PP) 4-Methylaminorex;
(QQ) N-Hydroxy-3,4-Methylenedioxyamphetamine;
(RR) Reserved;
(SS) Chlorophenylpiperazine (CPP);
(TT) N, N-Dimethylamphetamine;
(UU) 1-(1-(2-thienyl)cyclohexy)pyrrolidine;
(VV) 4-Bromo-2,5-Dimethoxyphenethylamine (DMPE);
(WW) Alpha-Ethyltryptamine;
(XX) Methcathinone;
(YY) Aminorex;
(ZZ) 4-iodo-2,5-dimethoxyamphetamine;
(AAA) 4-chloro-2,5-dimethoxyamphetamine;
(BBB) 3,4-Methylenedioxypyrovalerone (MDPV);
(CCC) 4-Methylmethcathinone (Mephedrone);
(DDD) 3,4-Methylenedioxymethcathinone (Methylone);
(EEE) 4-Methoxymethcathinone;
(FFF) Fluoromethcathinone;
(GGG) Fluorophenylpiperazine (FPP);
(HHH) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
(III) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
(JJJ) 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]- benzeneethanamine (25I-NBOMe);
(KKK) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]- benzeneethanamine (25C-NBOMe);
(LLL) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]- benzeneethanamine (25B-NBOMe);
(MMM) N,N-Diallyl-5-Methoxytryptamine (5-MeO-DALT);
(NNN) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(OOO) 2-(2,5-Dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl) ethanamine (25N-NBOMe);
(PPP) 4-acetoxy-N-ethyl-N-methyltryptamine (4-AcO-MET);
(QQQ) 4-nitro-2,5-dimethoxyphenethylamine (2C-N);
(RRR) 5-methoxy-N,N-methylisopropyltryptamine (5-MeO-MIPT);
(SSS) Methoxetamine;
(TTT) N-acetyl-3,4-methylenedioxymethcathinone;
(UUU) 3-(1,3-benzenodioxol-5-yl)-N,2-dimethylpropan-1-amine (3,4-methylenedioxymethamphetamine methyl homolog);
(VVV) (2-aminopropyl)-2,3-dihydrobenzofuran (APDB);
(WWW) 4-methyl-2,5-dimethoxy-N-[(2-methoxyphenyl)
(WWW) methyl]-benzeneethanamine (25D-NBOMe);
(XXX) 2-chloro-4,5-methylenedioxymethamphetamine;
(YYY) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
(ZZZ) 2-bromo-4,5-methylenedioxymethamphetamine;
(AAAA) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25H-NBOMe);
(BBBB) Methoxyphencyclidine (MeO-PCP);
(CCCC) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-OH-MiPT);
(DDDD) N, a -dimethyl-5-benzofuranethanamine (5-MAPB);
(EEEE) 1-(1-benzofuran-6-yl)propan-2-amine (6-APB);
(FFFF) 1-(1-benzofuran-5-yl)- N -ethylpropan-2-amine (5-EAPB);
(GGGG) Fluorophenmetrazine;
(HHHH) 5-methoxy-N,N-Dibutyltryptamine (5-MeO-DBT);
(IIII) 5-methoxy-N,N-Diisobutyltryptamine (5-MeO-DIBT);
(JJJJ) N-(1,4-dimethylpentyl)-3,4-dimethoxyamphetamine;
History. Code 1933, § 79A-806, enacted by Ga. L. 1974, p. 221, § 1; Ga. L. 1978, p. 1668, § 6; Ga. L. 1979, p. 859, § 5; Ga. L. 1980, p. 1746, § 4; Ga. L. 1981, p. 557, § 3; Ga. L. 1982, p. 2403, §§ 11, 16; Ga. L. 1984, p. 22, § 16; Ga. L. 1984, p. 1019, § 1; Ga. L. 1985, p. 1219, § 2; Ga. L. 1986, p. 1555, § 3; Ga. L. 1987, p. 261, § 1; Ga. L. 1989, p. 233, § 1; Ga. L. 1990, p. 8, § 16; Ga. L. 1990, p. 640, § 1; Ga. L. 1992, p. 1131, § 1; Ga. L. 1994, p. 169, §§ 1-3, 3.1; Ga. L. 1996, p. 356, § 1; Ga. L. 2001, p. 816, § 1; Ga. L. 2002, p. 415, § 16; Ga. L. 2003, p. 349, § 2; Ga. L. 2005, p. 1028, § 1/SB 89; Ga. L. 2006, p. 219, § 14/HB 1054; Ga. L. 2008, p. 169, §§ 1, 2/HB 1090; Ga. L. 2010, p. 338, § 1/HB 1309; Ga. L. 2010, p. 860, § 1/SB 353; Ga. L. 2011, p. 656, §§ 1, 2/SB 93; Ga. L. 2012, p. 40, §§ 2, 3/SB 370; Ga. L. 2013, p. 5, § 1/HB 57; Ga. L. 2013, p. 71, §§ 1, 1.1/HB 302; Ga. L. 2013, p. 141, § 16/HB 79; Ga. L. 2014, p. 217, §§ 1-3/HB 835; Ga. L. 2015, p. 883, §§ 1, 2/HB 211; Ga. L. 2016, p. 798, §§ 2, 3/HB 783; Ga. L. 2017, p. 14, §§ 1-4/HB 231; Ga. L. 2017, p. 417, §§ 7-1, 7-2/SB 104; Ga. L. 2018, p. 314, §§ 1-4/HB 830; Ga. L. 2018, p. 1112, § 16/SB 365; Ga. L. 2019, p. 820, § 1/HB 483; Ga. L. 2019, p. 1030, § 3/HB 213; Ga. L. 2021, p. 184, § 26/SB 195; Ga. L. 2021, p. 386, §§ 1-4/HB 367; Ga. L. 2022, p. 803, §§ 1 through 5/HB 963.
The 2016 amendment, effective May 3, 2016, rewrote subparagraph (3)(P); added subparagraphs (3)(BBBB) through (3)(DDDD); deleted subparagraph (12)(L.1), which read: “1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);” substituted “Indole carboxamides” for “(1-Pentylindol-3-yl)-(2,2,3,3 tetramethylcyclopropyl) methanone (UR-144)” in subparagraph (12)(M); substituted “Indole carboxylates” for “[1-(5-fluoropentyl)indole-3yl]-(2,2,3,3 tetramethylcyclopropyl) methanone (XLR11)” in subparagraph (12)(N); substituted “Indazole carboxylates” for “[1-(2-morpholin-4-ylethyl)-1H-indol-3-yl] -(2,2,3,3 tetramethylcyclopropyl) methanone (A-796,260)” in subparagraph (12)(P); substituted “Indole tetramethylcyclopropanecarbonyls” for “1-pentyl-3-(1-adamantylamido)indole (2NE1)” in subparagraph (12)(S); substituted “Napthoylbenzimidazoles” for “1-(5-fluoropentyl)-N-(tricyclo[3.31.13,7]de c-1-yl)-1H-indole-3-carboxamide (STS-135)” in subparagraph (12)(T); substituted “Naphthoylindazoles” for “N-1-naphthalenyl-1-pentyl-1H-indole-3-c arboxamide (NNEI)” in subparagraph (12)(V); deleted subparagraph (12)(W), which read: “N-(1-amino-3,3-dimethyl-1-oxo-butan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA);”; deleted subparagraph (12)(X), which read: “(1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl) (naphthalen-1-yl)methanone (AM-2201 benzimidazole analog);”; deleted subparagraph (12)(Y), which read: “Quinolin-8-yl-1-(4-fluorobenzyl)-1H-in= —dole-3-carboxylate (FUB-PB-22);”; deleted subparagraph (12)(Z), which read: “Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-ca rboxylate (FDU-PB-22);”; deleted subparagraph (12)(AA), which read: “Naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxyl ate (NM2201);”; deleted subparagraph (12)(BB), which read: “(1-(4-fluorobenzyl)-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144);”; deleted subparagraph (12)(CC), which read: “N-(1-amino-3-methyl-1-oxobutan-2-yl)- 1-(5-fluoropentyl) 1H-indole-3-carboxamide (5-fluoro-ABICA);”; and deleted subparagraph (12)(DD), which read: “1-naphthalenyl(1-pentyl-1H-indazol-3-yl)- methanone (THJ 018)”.
The 2017 amendments.
The first 2017 amendment, effective April 17, 2017, added subparagraphs (1)(RR) and (1)(SS); in paragraph (3), reserved subparagraphs (3)(CC), (3)(EE), (3)(JJ), (3)(KK), (3)(LL), (3)(MM), (3)(NN), and (3)(RR), which formerly read: “(CC) 3-methylfentanyl
“(EE) Para-flurofentanyl
“(JJ) Alpha-Methylthiofentanyl
“(KK) Acetyl-Alpha-Methylfentanyl
“(LL) 3-Methylthiofentanyl
“(MM) Beta-Hydroxyfentanyl
“(NN) Thiofentanyl
“(RR) Beta-Hydroxy-3-Methylfentanyl”;
substituted “Fluoromethcathinone” for “4-Fluoromethcathinone” in subparagraph (3)(FFF); added subparagraphs (3)(EEEE) and (3)(FFFF); in paragraph (4), reserved subparagraphs (4)(B) and (4)(C), which formerly read: “(B) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzyl-fentanyl)
“(C) N-(1-(2-thienyl)methyl-4-pi-peridyl)-N-phenylpropanamide (thenylfen- tanyl)”; substituted “; and” for the period at the end of subparagraph (12)(V); and added paragraphs (13) through (15). The second 2017 amendment, effective May 8, 2017, added identical subparagraphs (1)(RR) and (1)(SS) and identical paragraphs (13) through (15).
The 2018 amendments.
The first 2018 amendment, effective May 3, 2018, added paragraph (3)(GGGG); inserted “or alkoxy substitution” in division (12)(L)(ii); substituted the present provisions of division (13)(E)(ii) for the former provisions, which read: “Acetamide group, which itself can be further substituted with a cyclic alkyl group”; and substituted “diphenylethyl” for “diphenylethy” twice in paragraph (15). The second 2018 amendment, effective May 8, 2018, part of an Act to revise, modernize, and correct the Code, revised punctuation in subparagraph (12)(K).
The 2019 amendments.
The first 2019 amendment, effective May 7, 2019, added subparagraph (12)(W). The second 2019 amendment, effective May 10, 2019, added “, but not including such substance when found in hemp or hemp products as such terms are defined in Code Section 2-23-3” at the end of subparagraph (3)(P).
The 2021 amendments.
The first 2021 amendment, effective July 1, 2021, added the second sentence in subparagraph (3)(P). The second 2021 amendment, effective May 4, 2021, reserved subparagraphs (1)(K) and (1)(V), which formerly read: “Clonitazene” and “Etonitazene”, respectively; added subparagraph (1)(TT); added subparagraphs (3)(HHHH) through (3)(JJJJ); substituted “a cyclic or acyclic” for “an acyclic” in division (12)(L)(ii); substituted a semicolon for a period at the end of division (15)(B)(vi); and added paragraph (16).
The 2022 amendment, effective May 13, 2022, substituted “Brorphine” for “Reserved” in subparagraph (1)(K); added subparagraph (1)(UU); substituted “Para-methoxymethamphetamine (PMMA)” for “Reserved” in subparagraph (3)(KK); substituted “4,4'-dimethylaminorex” for “Reserved” in subparagraph (3)(LL); substituted “Methiopropamine” for “Reserved” in subparagraph (4)(C); substituted “an alkyl, alkoxy, or cyclic substitution;” for “a cyclic or acyclic alkyl, substitution or alkoxy; or” at the end of division (12)(L)(ii); and added division (13)(E)(v).
Code Commission notes.
Pursuant to Code Section 28-9-5, in 1986, in subparagraph (3)(DD) “N-ethyl-3” was substituted for “n-ethyl-3”.
Editor’s notes.
Ga. L. 2010, p. 338, not codified by the General Assembly, provides:
“WHEREAS, the General Assembly finds that there is a growing use of the unregulated synthetic cannabinoids commonly known as K2 or synthetic marijuana; and
“WHEREAS, preliminary studies indicate that the three synthetic cannabinoid substances unregulated in Georgia are from three to over 100 times more potent than THC, the active ingredient found in marijuana; and
“WHEREAS, many states as well as the federal government have already included one or more of these chemical compounds on Schedules of Controlled Substances, but none of these chemicals are currently listed on Georgia’s Schedule of Controlled Substances; and
“WHEREAS, synthetic cannabinoids are referred to as the new marijuana, and K2 is gaining in popularity at an alarming rate among high school and college students and persons on probation and parole; and
“WHEREAS, while having the same or stronger physiological effects as high potency marijuana, synthetic marijuana or K2 does not show a positive reading in an urinalysis test which adds to the desirability and increased growth among drug abusers and increases the threat to public health and safety by avoiding detection; and
“WHEREAS, the General Assembly should address the growing threat of synthetic cannabinoids to the health, safety, and welfare of our citizens before the problem becomes epidemic in the State of Georgia.”
Ga. L. 2012, p. 40, § 1/SB 370, not codified by the General Assembly, which provides for the annual update of the identity of controlled substances and dangerous drugs, is dedicated to the memory of Chase Corbitt Burnett and shall be known and may be cited as “Chase’s Law.”
Ga. L. 2021, p. 184, § 28/SB 195, not codified by the General Assembly, provides that: “Nothing in this Act shall be deemed to change, amend, or alter any criteria for applications for a Class 1 or Class 2 production license submitted to the Georgia Access to Medical Cannabis Commission on or prior to January 27, 2021.”
Administrative rules and regulations.
Registration requirements under Georgia Controlled Substances Act, Official Compilation of the Rules and Regulations of the State of Georgia, Rules of Georgia State Board of Pharmacy, Chapter 480-20.
Law reviews.
For article on the 2017 amendment of this Code section, see 34 Ga. St. U.L. Rev. 61 (2017).
For survey article on criminal law and procedure, see 34 Mercer L. Rev. 89 (1982).
For annual survey on criminal law, see 69 Mercer L. Rev. 73 (2017).

Structure Georgia Code